Medico-economic Study of Three Strategies of Sentinel Lymph Node Analysis in Operable Breast Cancer

Breast Cancer Clinical Trial

— SAGE  

Official title:

Multicentric, National, Prospective, Comparative, Non Randomized Study, Assessing Medico-economic Impact of Three Strategies of Sentinel Lymph Node Analysis in Immediately Operable Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02056886
• Other study ID #: ICO-N-2012-08
• Secondary ID: 2012-A01504-39
• Status: Completed
• Phase: N/A
• Start date: October 21, 2013
• Est. completion date: February 15, 2022

Study information

• Verified date: April 2022
• Source: Institut Cancerologie de l'Ouest
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Breast carcinoma requires frequently an adjuvant therapy after surgical excision: in this way, one of the major criteria indicating the need of adjuvant chemotherapy is the diagnosis of a metastatic lymph-node invasion, mainly in the axillary field. Axillary surgery is therefore mandatory at the diagnosis of breast carcinoma. For many years, in order to avoid unnecessary complications due to extensive axillary surgery (for instance, arm enlargement by lymphedema), a limited surgery is frequently performed on the first supposed invaded lymph-nodes (LN) called "sentinel" LN technique; if the sentinel LN are not invaded, extensive axillary surgery can be omitted. To decide it during the surgery, removed sentinel LN are cut in 3 to 4 slices which are examined immediately as smears (cytology) or frozen slices (pathology). However, due to hazard in cutting the LN, micro-metastases can be misdiagnosed. That is why a recent molecular biology method has been developed in which the total LN are crushed and blended, then analyzed by OSNA technique (One Step Nuclear Acid analysis) so as to amplify and detect the mRNA coding for cytokeratin-19 protein witnessing the LN metastatic invasion. A standardized automated technique is available with a mean time of 30 to 50 minutes according to the number of analyzed LN.

In 12 international studies (2830 cases) the consistency between OSNA technique and final pathology is of 91 to 98% and the sensitivity seems higher. Less than 5% of all breast carcinomas cells don't express CK-19 protein.

The use of OSNA technique requires a dedicated machine and a skilled pathologist, increasing slightly the operation time; however it allows to avoid the immediate and long-term complications due to the radical LN axillary surgery in case of negativity of the sentinel LN procedure. To date, the three techniques including extemporaneous examinations (OSNA or classical methods) or not (classical pathological analysis) have their own advantages and drawbacks.

"SAGE" study main objective is to compare these three techniques in terms of direct costs and Quality of Life impacts. The superiority of any of these three techniques is not the purpose of SAGE study, but the economic burden of OSNA technique in comparison with the 2 others in the standard setting in France.

Quality of Life and Pain evaluations will be performed immediately after surgery and during the 6 months after.

Description:

Today, standard treatment for early Breast carcinoma starts with a surgical step consisting of the tumor resection and sentinel lymph-node (SLN) detection, in order to select patients to be proposed for complementary axillary lymphadenectomy. This requested information may be obtained during the same operation time by intra operative examination, or after surgery with the consequence of a second surgical procedure when lymphadenectomy appears to be indicated. In France, three strategies are currently used for the management of sentinel lymph nodes:

• intra operative pathological frozen section examination followed by final pathological diagnosis,

• intra operative molecular biology using the OSNA technique (One Step Nuclear Acid analysis)

• no intra operative examination, but the final pathological examination. Each of these 3 strategies has advantage and drawbacks and their own cost. With more than 50000 new cases per year in France, Breast carcinoma, thanks to population screening, more and more small tumors are detected where such information about sentinel LN invasion is needed.

Our proposed study is a prospective, cost-effectiveness and comparative non randomised study where three strategies are evaluated in the current practice of the participating teams.

Main Objective :

• to evaluate in each of these 3 strategies for sentinel LN diagnosis, cost-effectiveness and cost-utility (QALY), Quality of Life,…

Secondary Objectives :

• rate of second surgery needed

• rate of mico-metastases or macro-metastases detected to build a decision score,

• follow-up of non re-operated patient despite positive sentinel LN,

• RNA collection from the crushed and blended sentinel LN

• Quality of Life evaluation through the surgical times using QLQ C30 and Br 23 scales.

Medical section :

At pre-operative consultation, patients will be informed to consent participating in our observational study, without any change in their treatment strategy. Inclusion parameters are strictly the same in the three groups.

At the time of surgery, if intra operative examination is planned, patient will be informed that a complete axillary dissection could be indicated.

Included patients will be followed 15 days after surgery and at 3 and 9 months. Then every 6 months during 2 years, then yearly.

Economical section :

Main objective of " SAGE " study is to light up decision maker in striking the balance of each strategy (induced costs and prevented costs) and results in terms of health as expressed by individuals preference depending on different health status, treatment strategies and clinical practice in French centers.

In our study, the medico-economical evaluation on such a quite National scale (17 different centers) takes place in a practice standardization prospect.

General methodology :

In each participating center, one of the 3 strategies for the sentinel LN analysis is currently used (with or without extemporaneous procedure).

Cost-effect evaluation will inventory all undertaken costs in each strategy and all induced positive or negative consequences, both at a qualitative and quantitative level using micro costing and macro costing evaluations. Evaluation of Quality of Life adjusted to health will be included to the cost effect analysis.

In our study, population studied with a localized breast carcinoma, are women aged between 18 and 65 years old and likely to be active : inclusion criteria are strictly the same in the 3 strategies studied.

In our study, we will consider Hospital and Health Insurance point of view. Hospital prospect will identify and value the cost paid by health institution due to the use of any of these 3 techniques.

Insurance Health prospect will value the costs of each treatment strategy including direct costs related to private medical care and not only those to be reimbursed to the hospital.

The study starts at the time of the sentinel LN excision and ends 9 months later, including the post-operative complications and the possible second surgery for axillary LN excision.

At all 920 patients will be included in the 20 participating team.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 858
• Est. completion date: February 15, 2022
• Est. primary completion date: January 2, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Infiltrating breast carcinoma histologically proven (lobular, ...)

2. unifocal,

3. T <3 cm (clinical), palpable or non-palpable tumor (smaller than a centimetre allowed),

4. N0 clinical axillary

5. Conservative surgery,

6. GS detection by isotopic or combined method,

7. Age <65 (for more frequent activity), and> 18 years.

8. Social protection

9. Signed Informed consent

Exclusion Criteria:

1. Recurrence of breast carcinoma,

2. History of ipsilateral breast reduction surgery,

3. Radical surgery.

4. History of lumpectomy

5. Neoadjuvant chemotherapy

6. Multi-focality

7. Neoadjuvant hormone therapy

8. < 18 years old

9. Pregnant or nursing patient or of childbearing age without effective contraception,

10. Legal incapacity or limited legal capacity. Medical or psychological conditions not allowing the subject to understand the study and sign the consent.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Surgery

Intervention

Procedure:
• SLN detection +/- complementary axillary lymphadenectomy
breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)

Locations

Country	Name	City	State
France	ICO Paul Papin	Angers
France	Institut Bergonie	Bordeaux
France	Jean Perrin	Clermont-Ferrand
France	Institut du Sein -Clinique Saint-Amé	Lambres-lez-Douai
France	Oscar Lambret	Lille
France	Institut Paoli Calmettes	Marseille
France	HEGP	Paris
France	Institut Curie	Paris
France	CHU	Pierre-Bénite
France	Eugène Marquis	Rennes
France	Henri BECQUEREL	Rouen
France	Institut Curie	Saint-Cloud
France	Clinique Mutualiste	Saint-Étienne
France	Jean-Marc cancérologie CLASSE	Saint-Herblain
France	CHU	Saint-Priest-en-Jarez
France	IUCT-O	Toulouse
France	Institut de Cancérlogie de Lorraine	Vandœuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Institut Cancerologie de l'Ouest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Medico-economic study : medical cost between 3 different sentinel lymph node analysis (histological analysis or molecular biology) in the management of patients treated for invasive breast carcinoma.	Several phases are differences to compare the costs of three strategies: surgery; hospitalization; follow-up	from surgery to 9 mounths later